Topoisomerase II Inhibitors Induce an Illegitimate Genome Rearrangement Common in Infant Leukemia

1 online resource (123 pages) : PDF

2013

University of North Carolina at Charlotte

Infant acute leukemias account for ~30% of all malignancy seen in childhood across the Western world. They are aggressive and characterized by rapid onset shortly after birth. The majority of these have rearrangements involving the MLL (mixed lineage leukemia) gene. Although MLL fusion to more than 75 genes have been identified, AF9 is one of its most common translocation partners. Since MLL breakpoint sequences associated with infant acute leukemia are similar to those in secondary AML following exposure to the topoisomerase II (topo II) poison etoposide, it has been hypothesized that exposure during pregnancy to biochemically similar compounds may promote infant acute leukemia. Some studies have shown an epidemiological link between bioflavonoid intake and increased incidence of MLL-rearranged infant leukemias. Hundreds of unregulated nutritional supplements are widely available and perceived to prevent cardiovascular disease, inflammation and cancer. However, their potential to promote leukemic translocations should be determined. My goal was to test the hypotheses that 1) MLL and AF9 breakpoint cluster regions (bcrs) undergo double strand breaks (DSBs), and are highly recombinogenic independent of chromosomal context, and in the absence of a leukemic fusion protein; and 2) a number of topoisomerase II inhibitors have the potential to promote these translocations analogous to those observed in infant leukemia. To test these hypotheses, I developed transgenic reporter cell lines such that a translocation between MLL and AF9 bcrs results in a full-length GFP transcript and quantifiable green fluorescence. I show here that topo II inhibitors such as the bioflavonoids genistein, quercetin, luteolin and myricetin lead to MLL-AF9 bcr translocations, genistein and quercetin being the most potent promoters. Notably, benzoquinone which is associated with non-MLL-rearranged leukemias do not promote MLL-AF9 translocations even at a high dose. I demonstrate here the sensitivity of the MLL and AF9 bcrs to topo II poisons and bioflavonoids independent of their normal chromatin context and independent of the formation of a leukemic fusion protein. In addition, this reporter gene system allows for rapid and reproducible screening of hundreds of compounds that may have the potential to promote leukemogenic translocations.

doctoral dissertations

Molecular biology

Ph.D.

Bioflavonoids
Double-Strand Breaks
Infant Acute Leukemia
In Utero Exposure
MLL
Topoisomerase II

Biology

Richardson, Christine

Clemens, Mark
Mukherjee, Pinku
Schrum, Laura
Fodor, Anthony

Thesis (Ph.D.)--University of North Carolina at Charlotte, 2013.

This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). For additional information, see http://rightsstatements.org/page/InC/1.0/.

Copyright is held by the author unless otherwise indicated.

Bariar_uncc_0694D_10475

http://hdl.handle.net/20.500.13093/etd:696